Trial Profile
An Open-label, Multicenter Study to Evaluate the Efficacy and Safety of Ranibizumab (0.5 mg) in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration Over 12 Months
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Nov 2015
Price :
$35
*
At a glance
- Drugs Ranibizumab (Primary)
- Indications Choroidal neovascularisation
- Focus Registrational; Therapeutic Use
- Acronyms EXTEND II
- Sponsors Novartis
- 06 Nov 2015 New trial record